Clinical trials: Cancer Patient
Advanced Solid Tumor, Advanced Cancer
NBE-002 in Patients With Advanced Solid Tumors
This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04441099
- Testing
- NBE-002
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- NBE-Therapeutics AG
Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
This expanded access study has being designed following a demand from the FDA, given the increase in the number of request for single patient INDs for lorlatinib
- Trial name
- NCT03178071
- Testing
- Lorlatinib
- Where
- 49 sites in United States
- Sponsor
- Pfizer
Metastasis, Breast Cancer
A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated…
- Trial name
- ATTAIN (NCT02915744)
- Testing
- NKTR-102, Eribulin, Ixabepilone
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 178 people
- Sponsor
- Nektar Therapeutics
Breast Cancer, Malignant Neoplasm of Breast
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
Palbociclib, the first oral CDK4/6 inhibitor, is an approved medicine indicated for the treatment of a kind of advanced/metastatic breast cancer (MBC), called hormone receptors positive (HR+)/ Human epidermal growth factor…
- Trial name
- NCT06495164
- Testing
- Palbociclib, Aromatase inhibitor, Ribociclib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Lymphoma
Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
The purpose of this study is to assess the antitumor efficacy of single-agent brentuximab vedotin 1.8 mg/kg administered intravenously (IV) every 3 weeks, as measured by the overall objective response rate (ORR) in patients with…
- Trial name
- NCT01909934
- Testing
- Brentuximab vedotin
- Where
- 40 sites in Belgium, Croatia and 8 more
- Volunteers
- 50 people
- Sponsor
- Takeda
Recurrent Glioblastoma
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
This is an open-label, multicenter, phase II study to evaluate the safety, efficacy, and pharmacokinetic characteristics of BL-B01D1 for Injection in patients with recurrent glioblastoma.
- Trial name
- NCT06598787
- Testing
- BL-B01D1 for Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Colorectal Neoplasms
A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
The primary objective of the Phase 2 portion of the study is to characterize the clinical activity of maintenance therapy with GRT-C901/GRT-R902 (patient-specific vaccines) in combination with checkpoint inhibitors in addition to…
- Trial name
- NCT05141721
- Testing
- GRT-C901, GRT-R902, Atezolizumab
- Where
- 43 sites in United States
- Volunteers
- 700 people
- Sponsor
- Seattle Project Corporation
Advanced Tumors
Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors
This project is an open, dose escalation and expansion phase I clinical study. The first phase is a dose escalation study, and the second phase is a dose expansion study based on the Maximum tolerated dose (MTD) / Recommended…
- Trial name
- NCT05213767
- Testing
- TQB2916 injection
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Pancreatic Cancer
Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether nitrocamptothecin is more effective than fluorouracil for pancreatic cancer.
- Trial name
- NCT00005871
- Testing
- fluorouracil, rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Hepatocellular Carcinoma
A Study of Anlotinib in Patients With Hepatocellular Carcinoma
To assess the primary effects and safety of Anlotinib with placebo in patients with Hepatocellular Carcinoma(HCC).
- Trial name
- ALTER0802 (NCT02809534)
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Malignant Solid Tumor, Solid Tumor
A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread
The purpose of this study is to evaluate two different dosing regimens of LY2334737 in participants with cancer that is advanced and/or has spread to other parts of the body. Information about side effects will be collected.
- Conditions
- Malignant Solid Tumor, Solid Tumor, Metastatic Tumor
- Trial name
- NCT01648764
- Testing
- LY2334737
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 73 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumor
Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors
This study is a Phase 1b, single-center, open-label, dose-finding trial designed to identify the Recommended Phase 2 Dose (RP2D) of STI 6129 by assessing the safety, preliminary efficacy, and immunogenicity in subjects with any…
- Trial name
- NCT05584709
- Testing
- STI-6129
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sorrento Therapeutics, Inc.
EBV-induced Lymphomas, EBV-associated Malignancies
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
- Trial name
- NCT00002663
- Testing
- Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Atara Biotherapeutics
Common Warts, Common Warts (Verruca Vulgaris)
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-302; referred to as COVE-3 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy and safety of YCANTH (VP-102/TO-208)…
- Conditions
- Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
- Trial name
- COVE-3 (NCT07637734)
- Testing
- VP-102 (US) / TO-208 (Japan), Vehicle (US) / Vehicle (Japan)
- Where
- 20 sites in United States, Japan
- Volunteers
- 300 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Advanced Solid Tumor
Study of ZG0895.HCl in Patients With Advanced Solid Tumors
The primary objective of this study is to assess the tolerability and safety of ZG0895.HCl, and to assess the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) of ZG0895.HCl.
- Trial name
- NCT05877664
- Testing
- ZG0895 Hydrochloride for Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Thrombocytopaenia
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
The present study is a randomized, blinded, placebo-controlled, two-Phase, sequential cohort, dose finding study to assess the safety and efficacy of eltrombopag in patients with solid tumors receiving gemcitabine monotherapy or…
- Trial name
- NCT01147809
- Testing
- Eltrombopag olamine
- Where
- 86 sites in United States, Belgium and 11 more
- Volunteers
- 130 people
- Sponsor
- GlaxoSmithKline
Melanoma, NSCLC
A Study of BCD-135 in Patients With Advanced Solid Tumors
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-135 (JSC BIOCAD, Russia) in Patients with Advanced Solid Tumors
- Conditions
- Melanoma, NSCLC, Renal Cell Carcinoma, Bladder Cancer
- Trial name
- NCT03464032
- Testing
- BCD-135
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Biocad
Advanced Solid Tumors
Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors
This study is the first-in-human (Phase I/II) trial of SYS6045, a multicenter, open-label, dose-escalation and dose-expansion clinical study.
- Trial name
- NCT07122063
- Testing
- SYS6045
- Where
- China
- Volunteers
- 266 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Diffuse Large B-cell Lymphoma
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
The purpose of this study is to confirm whether the bispecific T-cell engager blinatumomab is effective and safe in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT01741792
- Testing
- Blinatumomab
- Where
- 6 sites in Germany
- Volunteers
- 25 people
- Sponsor
- Amgen Research (Munich) GmbH
Relapsed/Refractory Acute Myeloid Leukemia
Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia
This study will evaluate the safety and efficacy of NK520 in the treatment of relapsed/refractory acute myeloid leukemia. NK520 will be administered by intravenous injection.
- Trial name
- NCT06541444
- Testing
- NK520
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.